New Orleans—In the wake of the highly publicized and tragic death of a patient who participated in a gene therapy trial at the University of Pennsylvania comes some good news: encouraging early results from two studies reported here at the annual meeting of the American Society of Hematology, one aimed at a lethal form of inherited immunodeficiency and the other targeting hemophilia B.
If the promising but preliminary results from the two phase 1 trials hold up, the two studies may be the first to provide evidence of clinical benefit for patients treated with gene therapy.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.